Previous 10 | Next 10 |
Company Thesis Northwest Biotherapeutics' ( NWBO ) flagship product, DCVax (Dendritic cell vaccine for the treatment of glioblastoma) has seen its clinical investigation running well beyond schedule. While preliminary results on the entire study population are out, they raise more questions ...
As a statistician and math enthusiast, it was torture reviewing released Northwest Bio’s ( OTCQB:NWBO ) blinded data, and updated statistics showcasing the blinded results of the DCVax-L Phase III trial from back in June 2018. Reading the positive outlook of the trial through the ey...
BETHESDA, Md. , Dec. 12, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition ...
BETHESDA, Md. , Dec. 11, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch , Chief Technical Officer of NW Bio, is presenting a...
BETHESDA, Md. , Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC. As previously repor...
BETHESDA, Md. , Sept. 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management team with the addition of Dr. ...
BETHESDA, Md. , June 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today highlights from Dr. Marnix Bosch's Program Update in the Industry ...
BETHESDA, Md. , May 30, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Indus...
BETHESDA, Md. , May 28, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement with Cognate BioServices, In...
BETHESDA, Md. , Feb. 26, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations. ...
News, Short Squeeze, Breakout and More Instantly...
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- No...
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...